Characteristics of patients and controls
| . | Patients . | Controls . | P . |
|---|---|---|---|
| n | 14 | 47 | — |
| Mo/y of transplant, range | 10/2004 to 2/2007 | 3/1998 to 10/2004 | — |
| Mean age, y (range) | 8 (1-16) | 7.1 (1-17) | NS |
| Patient sex, no. (%) | |||
| Male | 9 (61) | 28 (60) | NS |
| Female | 5 (39) | 19 (40) | NS |
| Original disease, no. (%) | |||
| Hematologic malignancies | 11 (79) | 35 (75) | (Distribution) .2 |
| ALL | 4 (36) | 21 (57) | — |
| CR1 | 0 | 2 | — |
| CR2 | 3 | 11 | — |
| Greater than CR2 | 1 | 8 | — |
| AML | 7 (64) | 12 (34) | — |
| CR1 | 0 | 2 | — |
| CR2 | 4 | 5 | — |
| Greater than CR2 | 0 | 2 | — |
| Secondary | 1 | 1 | — |
| Refractory | 2 | 2 | — |
| CML, chronic phase | 0 (0) | 2 (6) | — |
| Immune deficiencies | 2 (14) | 2 (4) | — |
| Other nonmalignant disorders | 1 (7) | 10 (21) | — |
| Fanconi anemia | 1 | 4 | — |
| Hemoglobinopathies | — | 1 | — |
| HLH | — | 4 | — |
| Other | — | 1 | — |
| Donor sex, Male-female ratio | 8:6 | 27:20 | NS |
| Conditioning regimen, TBI-based/chemotherapy-based, no. (%) | 9/5 (64/36) | 30/17 (63/37) | NS |
| Graft characteristics | |||
| No. of CD34+ cells infused ×106/kg, median (range) | 21.5 (11.6-38.6) | 24.3 (12.1-47.5) | NS |
| No. of CD3+ cells infused ×105/kg, mean (SD) | 0.3 (0.3) | 0.5 (0.7) | NS |
| Hematopoietic recovery, median (range) | |||
| No. of d to PMN recovery* | 12 (10-17) | 13 (9-28) | .15 |
| No. of d to PLT recovery† | 10 (9-18) | 13 (9-100) | .13 |
| No. of d to reticulocyte recovery‡ | 12 (10-31) | 23 (9-41) | .03 |
| No. of d to leukocyte recovery§ | 11.5 (9-15) | 14.9 (10-26) | .009 |
| Post-HSCT complications, no. (%) | |||
| Graft failure | 0 (0) | 7 (15) | .14 |
| Primary | — | 4 | — |
| Secondary | — | 3 | — |
| Acute GvHD | — | — | .15 |
| Grade I-II | 2 (14) | 12 (26) | — |
| Grade III-IV | 0 (0) | 2 (4) | — |
| Chronic GvHD | 1 (7) | 6 (13) | .34 |
| Limited | 1 | 4 | — |
| Extensive | 0 | 2 | — |
| . | Patients . | Controls . | P . |
|---|---|---|---|
| n | 14 | 47 | — |
| Mo/y of transplant, range | 10/2004 to 2/2007 | 3/1998 to 10/2004 | — |
| Mean age, y (range) | 8 (1-16) | 7.1 (1-17) | NS |
| Patient sex, no. (%) | |||
| Male | 9 (61) | 28 (60) | NS |
| Female | 5 (39) | 19 (40) | NS |
| Original disease, no. (%) | |||
| Hematologic malignancies | 11 (79) | 35 (75) | (Distribution) .2 |
| ALL | 4 (36) | 21 (57) | — |
| CR1 | 0 | 2 | — |
| CR2 | 3 | 11 | — |
| Greater than CR2 | 1 | 8 | — |
| AML | 7 (64) | 12 (34) | — |
| CR1 | 0 | 2 | — |
| CR2 | 4 | 5 | — |
| Greater than CR2 | 0 | 2 | — |
| Secondary | 1 | 1 | — |
| Refractory | 2 | 2 | — |
| CML, chronic phase | 0 (0) | 2 (6) | — |
| Immune deficiencies | 2 (14) | 2 (4) | — |
| Other nonmalignant disorders | 1 (7) | 10 (21) | — |
| Fanconi anemia | 1 | 4 | — |
| Hemoglobinopathies | — | 1 | — |
| HLH | — | 4 | — |
| Other | — | 1 | — |
| Donor sex, Male-female ratio | 8:6 | 27:20 | NS |
| Conditioning regimen, TBI-based/chemotherapy-based, no. (%) | 9/5 (64/36) | 30/17 (63/37) | NS |
| Graft characteristics | |||
| No. of CD34+ cells infused ×106/kg, median (range) | 21.5 (11.6-38.6) | 24.3 (12.1-47.5) | NS |
| No. of CD3+ cells infused ×105/kg, mean (SD) | 0.3 (0.3) | 0.5 (0.7) | NS |
| Hematopoietic recovery, median (range) | |||
| No. of d to PMN recovery* | 12 (10-17) | 13 (9-28) | .15 |
| No. of d to PLT recovery† | 10 (9-18) | 13 (9-100) | .13 |
| No. of d to reticulocyte recovery‡ | 12 (10-31) | 23 (9-41) | .03 |
| No. of d to leukocyte recovery§ | 11.5 (9-15) | 14.9 (10-26) | .009 |
| Post-HSCT complications, no. (%) | |||
| Graft failure | 0 (0) | 7 (15) | .14 |
| Primary | — | 4 | — |
| Secondary | — | 3 | — |
| Acute GvHD | — | — | .15 |
| Grade I-II | 2 (14) | 12 (26) | — |
| Grade III-IV | 0 (0) | 2 (4) | — |
| Chronic GvHD | 1 (7) | 6 (13) | .34 |
| Limited | 1 | 4 | — |
| Extensive | 0 | 2 | — |
ALL indicates acute lymphoblastic leukemia; CR, complete remission; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HLH, hemophagocytic lymphohistiocytosis; TBI, total body irradiation; PMN, polymorphonuclear neutrophil; PLT, platelet; HSCT, hematopoietic stem cell transplantation; GvHD, graft-versus-host-disease; SD, standard deviation; NS, nonsignificant; and —, not applicable.
Time needed to reach an absolute neutrophil count equal to or greater than 0.5×109/L.
Time needed to reach an unsupported platelet count equal to or greater than 20×109/L.
Time needed to reach a reticulocyte count equal to or greater than 20×109/L.
Time needed to reach a leukocyte count equal to or greater than 1×109/L.